Skip to main content
. 2021 Nov 9;50(D1):D316–D325. doi: 10.1093/nar/gkab996

Figure 1.

Figure 1.

Overview of the ReMap 2022 database growth. (A) Analysed Human datasets growth in ReMap 2022 compared to 2020, 2018 and 2015, removed datasets from the new quality control (QC2) in yellow. (B) Human ChIP-seq peaks growth in ReMap 2022 compared to previous releases, yellow corresponds to removed peaks. (C, D) Evolution of the number of datasets across the top 15 transcriptional regulators (TRs) and biotypes between ReMap 2022 and 2020. (E) Analysed Arabidopsis thaliana datasets in 2022 compared to 2020. (F) Arabidopsis regulatory peaks growth in ReMap 2022 compared to 2020, yellow corresponds to removed peaks (G, H) Evolution of the number of datasets across the top 15 transcriptional regulators and biotypes between the two Arabidopsis ReMap catalogs. (I) Analysed ChIP-seq datasets for the ReMap 2022 Mus musculus catalog, removed datasets from QC2 in yellow. (J) Size of the Mus musculus regulatory catalog, before and after QC2 (yellow). (K, L) Number of datasets for the top 15 TRs and top 6 biotypes. (M) Transcriptional regulators shared between the Human and Mouse regulatory catalogs. (N) Analysed ChIP-seq datasets for the ReMap 2022 Drosophila melanogaster catalog, removed datasets from QC2 in yellow. (O) Size of the Drosophila melanogaster regulatory catalog, before and after QC2 (yellow). (P,Q) Number of datasets for the top 15 TRs and top 6 biotypes.

HHS Vulnerability Disclosure